PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 3:48 AM ET

Sponsor Check › Person

DH

David F. Hale

Named as an officer, director or promoter on SEC Form D filings · CA · Jun 12, 2009 → Mar 8, 2021

19deals (issuers)
$387.4Mreported sold
663investors
87Form D filings
2009–2021years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:18 AM ET · SEC enforcement last checked: not yet

The short version

David F. Hale is listed as an executive officer, director, and promoter on 87 SEC Form D filings by 19 issuers between Jun 2009 and Jan 2026. Largest by amount reported sold: Neurelis, Inc. (San Diego, CA — biotechnology — 2010–2021; $114.8M reported sold to 26 investors), Oncternal Therapeutics, Inc. (San Diego, CA — biotechnology — 2020; $48.5M reported sold to 12 investors), Zerigo Health, Inc. (San Diego, CA — other health care — 2014–2019; $43M reported sold to 51 investors), Neurana Pharmaceuticals, Inc. (San Diego, CA — biotechnology — 2017–2020; $41.9M reported sold to 14 investors), Histogen Inc. (San Diego, CA — biotechnology — 2010–2013; $25.3M reported sold to 21 investors) and 14 more (all listed below).

What this means That is a lot of deals — 19 separate companies raised money with this person listed as executive officer, director, and promoter, over about 17 years. Across those companies the filings report $387.4M sold in total.

Listed alongside Kathleen D. Scott (23 shared filings), Cam L. Garner (18 shared filings), James B. Breitmeyer, M.D., Ph.D. (13 shared filings), Gerald T. Proehl (12 shared filings), Mary Fisher (11 shared filings) and 165 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around David. Each name links to their own page.

The issuers belong to 4 sponsor groups: Colorescience (2 issuers, $18.3M reported sold, 2012–2020), Dermata Therapeutics (2 issuers, $7.12M reported sold, 2015–2026), Oncternal Therapeutics (2 issuers, $23.5M reported sold, 2014–2020) and Histogen (2 issuers, $20.3M reported sold, 2010–2022).

What this means This person is listed across more than one sponsor team; each group page shows that team's full track record.

Public records searched: federal courts (CourtListener / RECAP), state securities regulators (AZ, CA, DE, TX, WA) — 1 court case matching the name, 13 bankruptcy cases matching the name listed in Key records below. Not yet searched: SEC enforcement releases (search queued; results are added automatically).

What this means 14 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

What the community is saying

Nothing found on Reddit, BiggerPockets or community forums for high-net-worth investors (searched Oct 24, 2026) — search queued; this line updates when it has run.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

1 case: 1 judgment

US v. HALE, DAVID W. judgment
District Court, N.D. California · No. · Filed Mar 31, 1987 · Closed Sep 14, 1987 · Nature of suit: 190 Other contract actions
Role of HALE, DAVID W.: Defendant · Outcome: Terminated 1987-09-14 — FJC Integrated Database disposition: Judgment on default; judgment for plaintiff Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 24, 2026, 2:18 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

Not yet searched — search queued

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched.

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.

SEC search queued. Results are added automatically.

3. Bankruptcies

13 cases: 13 closed (disposition not in docket feed)

David B. Hale closed
United States Bankruptcy Court, N.D. California · No. 21-30646 · Filed Sep 15, 2021 · Closed Sep 7, 2022
Role of David B. Hale: Debtor · Outcome: Case closed 2022-09-07 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David Hale and Kymberly Hale closed
United States Bankruptcy Court, C.D. California · No. 2:20-bk-16872 · Filed Jul 30, 2020 · Closed Nov 3, 2020
Role of David Hale and Kymberly Hale: Debtor · Outcome: Case closed 2020-11-03 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David W. Hale and Traci L. Hale closed
United States Bankruptcy Court, E.D. California · No. 19-15197 · Filed Dec 15, 2019 · Closed Sep 4, 2020
Role of David W. Hale and Traci L. Hale: Debtor · Outcome: Case closed 2020-09-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David B. Hale closed
United States Bankruptcy Court, N.D. California · No. 19-31015 · Filed Sep 25, 2019 · Closed Apr 14, 2020
Role of David B. Hale: Debtor · Outcome: Case closed 2020-04-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David Hale closed
United States Bankruptcy Court, C.D. California · No. 6:18-bk-12363 · Filed Mar 23, 2018 · Closed Jul 3, 2018
Role of David Hale: Debtor · Outcome: Case closed 2018-07-03 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA)
David R Hale closed
United States Bankruptcy Court, N.D. California · No. 11-53371 · Filed Apr 10, 2011 · Closed Mar 18, 2013
Role of David R Hale: Debtor · Outcome: Case closed 2013-03-18 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David Hale closed
United States Bankruptcy Court, N.D. California · No. 10-57577 · Filed Jul 23, 2010 · Closed Nov 17, 2010
Role of David Hale: Debtor · Outcome: Case closed 2010-11-17 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA)
David A Hale closed
United States Bankruptcy Court, S.D. California · No. 09-19722 · Filed Dec 23, 2009 · Closed Apr 5, 2010
Role of David A Hale: Debtor · Outcome: Case closed 2010-04-05 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David J. Hale and Electra L. Hale closed
United States Bankruptcy Court, S.D. California · No. 09-15459 · Filed Oct 12, 2009 · Closed Jan 14, 2010
Role of David J. Hale and Electra L. Hale: Debtor · Outcome: Case closed 2010-01-14 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David B. Hale closed
United States Bankruptcy Court, N.D. California · No. 04-31548 · Filed May 28, 2004 · Closed Sep 10, 2004
Role of David B. Hale: Debtor · Outcome: Case closed 2004-09-10 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David G Hale closed
United States Bankruptcy Court, C.D. California · No. 9:97-bk-11441 · Filed Mar 21, 1997 · Closed May 28, 1997
Role of David G Hale: Debtor · Outcome: Case closed 1997-05-28 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David G. Hale closed
United States Bankruptcy Court, C.D. California · No. 9:97-bk-10363 · Filed Jan 27, 1997 · Closed Apr 9, 1997
Role of David G. Hale: Debtor · Outcome: Case closed 1997-04-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
David J. Hale and Electra L. Hale closed
United States Bankruptcy Court, S.D. California · No. 95-00762 · Filed Jan 25, 1995 · Closed Jan 6, 1997
Role of David J. Hale and Electra L. Hale: Debtor · Outcome: Case closed 1997-01-06 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 240 federal dockets); 6 people with this name in Form D filings; court in the person's filing state (CA); middle initial differs
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:18 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Not made for individual people — comparisons cover issuers and sponsor groups

5. Money to insiders

9 of 69 offerings report sales commissions totalling $5,173,722; 4 report finder's fees totalling $410,238; 1 reports proceeds to related persons totalling $34,000. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jan 7, 2026 D
Dermata Therapeutics, Inc.
File 021-569228
$342,500 (est.)$0$0 (est.)
Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.
H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗EDGAR ↗
Feb 4, 2025 D/A
Dermata Therapeutics, Inc.
File 021-536542
$174,751$0$0 (est.)
Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.
H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗EDGAR ↗
Sep 27, 2024 D
Dermata Therapeutics, Inc.
File 021-525299
$345,000 (est.)$0$0 (est.)
Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.
H.C. Wainwright & Co., LLC BrokerCheck CRD 000000375 ↗EDGAR ↗
Jun 12, 2023 D
Dermata Therapeutics, Inc.
File 021-483997
$0 (est.)$0 (est.)$0 (est.)H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗EDGAR ↗
Mar 8, 2021 D
Neurelis, Inc.
File 021-391462
$2,400,000$0$0Aquilo Partners, L.P. BrokerCheck CRD 114909 ↗EDGAR ↗
Mar 1, 2021 D
Adigica Health, Inc.
File 021-390828
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2020 D
Oncternal Therapeutics, Inc.
File 021-383955
$0$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗
Rodman & Renshaw, LLC BrokerCheck CRD 281264 ↗		EDGAR ↗
Dec 10, 2020 D
Dermata Therapeutics, LLC
File 021-382898
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Nov 24, 2020 D
Oncternal Therapeutics, Inc.
File 021-381439
$0$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗
Rodman & Renshaw, LLC BrokerCheck CRD 281264 ↗		EDGAR ↗
Oct 27, 2020 D
Adigica Health, Inc.
File 021-378912
$0$0$0None listed on this filingEDGAR ↗
Oct 16, 2020 D/A
Neurelis, Inc.
File 021-359627
$0$0$0None listed on this filingEDGAR ↗
Sep 9, 2020 D
Oncternal Therapeutics, Inc.
File 021-375153
$0$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗
Rodman & Renshaw, LLC BrokerCheck CRD 281264 ↗		EDGAR ↗
Aug 3, 2020 D
Oncternal Therapeutics, Inc.
File 021-372298
$381,336$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗
Rodman & Renshaw, LLC BrokerCheck CRD 281264 ↗		EDGAR ↗
Jun 3, 2020 D
Oncternal Therapeutics, Inc.
File 021-368243
$459,765$0$0H.C. Wainwright & Co., LLC BrokerCheck CRD 375 ↗
Rodman & Renshaw, LLC BrokerCheck CRD 281264 ↗		EDGAR ↗
Feb 26, 2020 D/A
Neurana Pharmaceuticals, Inc.
File 021-312331
$0$0$0None listed on this filingEDGAR ↗
Nov 15, 2019 D/A
Zerigo Health, Inc.
File 021-334344
$24,000$0$0IFS Securities BrokerCheck CRD 40375 ↗EDGAR ↗
Nov 6, 2019 D
Zerigo Health, Inc.
File 021-352681
$0$0$0None listed on this filingEDGAR ↗
Jun 6, 2019 D
BIOCEPT INC
File 021-341255
$0$0$0None listed on this filingEDGAR ↗
Mar 29, 2019 D
BIOCEPT INC
File 021-336072
$489,090$50,000$0None listed on this filingEDGAR ↗
Feb 14, 2019 D
Recros Medica, Inc.
File 021-332906
$0$0$0None listed on this filingEDGAR ↗
Feb 7, 2019 D
Adigica Health, Inc.
File 021-332401
$0$0$0None listed on this filingEDGAR ↗
Feb 7, 2019 D
Adigica Health, Inc.
File 021-332402
$0$0$0None listed on this filingEDGAR ↗
Nov 21, 2018 D
Oncternal Therapeutics, Inc.
File 021-326302
$0$0$0None listed on this filingEDGAR ↗
Nov 20, 2018 D
Neurelis, Inc.
File 021-326282
$0$0$0None listed on this filingEDGAR ↗
Oct 3, 2018 D
BIOCEPT INC
File 021-322732
$0$175,238$0None listed on this filingEDGAR ↗
Aug 24, 2018 D
Neurelis, Inc.
File 021-320006
$0$0$0None listed on this filingEDGAR ↗
Jul 3, 2018 D
Zerigo Health, Inc.
File 021-316051
$0$0$0None listed on this filingEDGAR ↗
May 14, 2018 D/A
Neurana Pharmaceuticals, Inc.
File 021-282295
$0$0$0None listed on this filingEDGAR ↗
May 7, 2018 D
Dermata Therapeutics, LLC
File 021-311804
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
May 7, 2018 D
Dermata Therapeutics, LLC
File 021-311805
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Dec 7, 2017 D/A
Neurelis, Inc.
File 021-277803
$0$0$0None listed on this filingEDGAR ↗
Sep 27, 2017 D
Oncternal Therapeutics, Inc.
File 021-295508
$0$0$0None listed on this filingEDGAR ↗
Aug 14, 2017 D
BIOCEPT INC
File 021-292759
$0$110,000$0None listed on this filingEDGAR ↗
Jul 27, 2017 D/A
Zerigo Health, Inc.
File 021-222095
$0$0$0None listed on this filingEDGAR ↗
Jul 25, 2017 D/A
Recros Medica, Inc.
File 021-266433
$0$0$0None listed on this filingEDGAR ↗
Jul 24, 2017 D
Zerigo Health, Inc.
File 021-291345
$0$0$0None listed on this filingEDGAR ↗
Apr 10, 2017 D
BIOCEPT INC
File 021-284375
$557,280$75,000$0None listed on this filingEDGAR ↗
Mar 27, 2017 D
Colorescience Inc
File 021-283385
$0$0$0None listed on this filingEDGAR ↗
Mar 23, 2017 D/A
Oncternal Therapeutics, Inc.
File 021-245323
$0$0$0None listed on this filingEDGAR ↗
Dec 19, 2016 D
MDREJUVENA, INC.
File 021-276576
$0$0$0None listed on this filingEDGAR ↗
Aug 23, 2016 D/A
Recros Medica, Inc.
File 021-224443
$0$0$0None listed on this filingEDGAR ↗
Aug 17, 2016 D
Adigica Health, Inc.
File 021-269089
$0$0$0None listed on this filingEDGAR ↗
Jul 8, 2016 D
Oncternal Therapeutics, Inc.
File 021-266615
$0$0$0None listed on this filingEDGAR ↗
Jun 8, 2016 D
Oncternal Therapeutics, Inc.
File 021-264575
$0$0$0None listed on this filingEDGAR ↗
May 18, 2016 D
Zerigo Health, Inc.
File 021-263432
$0$0$0None listed on this filingEDGAR ↗
May 18, 2016 D
Zerigo Health, Inc.
File 021-263434
$0$0$0None listed on this filingEDGAR ↗
Dec 23, 2015 D
BIOCEPT INC
File 021-253697
$0$0$0None listed on this filingEDGAR ↗
Oct 22, 2015 D/A
MDREJUVENA, INC.
File 021-227534
$0$0$0None listed on this filingEDGAR ↗
Jul 16, 2015 D
Neurelis, Inc.
File 021-243911
$0$0$0None listed on this filingEDGAR ↗
Jul 13, 2015 D
IDUN PHARMACEUTICALS INC
File 021-243499
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2015 D
Dermata Therapeutics, LLC
File 021-241620
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Feb 4, 2015 D/A
IDUN PHARMACEUTICALS INC
File 021-212450
$0$0$0None listed on this filingEDGAR ↗
Feb 3, 2015 D
Dermata Therapeutics, LLC
File 021-233387
$0 (est.)$0 (est.)$0 (est.)None listed on this filingEDGAR ↗
Sep 22, 2014 D
Colorescience Inc
File 021-225111
$0$0$0None listed on this filingEDGAR ↗
Mar 5, 2014 D
Oncternal Therapeutics, Inc.
File 021-212910
$0$0$0None listed on this filingEDGAR ↗
Jun 13, 2013 D
Histogen Inc.
File 021-197943
$0$0$0None listed on this filingEDGAR ↗
May 31, 2013 D
Colorescience Inc
File 021-197315
$0$0$0N/A no CRD number reportedEDGAR ↗
Apr 18, 2013 D
Ridge Diagnostics, Inc.
File 021-195230
$0$0$34,000
The amount provided in this Item 16 represents salary payable to certain executive officers of the Issuer.
None listed on this filingEDGAR ↗
Dec 31, 2012 D
Colorescience
File 021-189204
$0$0$0None listed on this filingEDGAR ↗
Aug 14, 2012 D
Agility Clinical, Inc.
File 021-182674
$0$0$0None listed on this filingEDGAR ↗
Mar 19, 2012 D
Ridge Diagnostics, Inc.
File 021-175187
$0$0$0None listed on this filingEDGAR ↗
Jan 13, 2012 D
SKINMEDICA INC
File 021-171888
$0$0$0None listed on this filingEDGAR ↗
Sep 30, 2011 D
Neurelis, Inc.
File 021-166626
$0$0$0None listed on this filingEDGAR ↗
Feb 17, 2011 D
Histogen Inc.
File 021-155526
$0$0$0None listed on this filingEDGAR ↗
Oct 28, 2010 D
Histogen Inc.
File 021-149755
$0$0$0None listed on this filingEDGAR ↗
Jun 11, 2010 D
Ridge Diagnostics, Inc.
File 021-143317
$0$0$0None listed on this filingEDGAR ↗
Feb 3, 2010 D
Neurelis, Inc.
File 021-138380
$0$0$0None listed on this filingEDGAR ↗
Jul 15, 2009 D
Somaxon Pharmaceuticals, Inc.
File 021-89181
$0$0$0None listed on this filingEDGAR ↗
Jun 12, 2009 D
SKINMEDICA INC
File 021-48011
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 19

Every issuer that named David F. Hale on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

DT
Biotechnology · group: Dermata Therapeutics

Dermata Therapeutics, Inc.

San Diego, CA · Jun 12, 2023 → Jan 7, 2026 · 5 filings
  • Jan 7, 2026 · D · $4,124,591 sold of $4,124,591 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 4, 2025 · D/A · $2,550,000 sold of $2,550,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 28, 2025 · D · $2,550,000 sold of $2,550,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 27, 2024 · D · $3,498,089 sold of $3,498,089 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2023 · D · $0 sold of Indefinite · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $4.12M from 14 investors (100% of the $4.12M target) as of the latest filing. David is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

N
Biotechnology

Neurelis, Inc.

San Diego, CA · Feb 3, 2010 → Mar 8, 2021 · 10 filings
  • Mar 8, 2021 · D · $114,759,923 sold of $120,021,902 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 16, 2020 · D/A · $42,098,007 sold of $42,098,007 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 3, 2020 · D · $15,348,001 sold of $15,348,001 · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 20, 2018 · D · $40,500,000 sold of $40,500,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 24, 2018 · D · $5,200,000 sold of $15,000,000 · 11 investors · min. $50,000 · role: Director EDGAR ↗
  • Dec 7, 2017 · D/A · $15,000,000 sold of $20,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 6, 2017 · D · $10,000,000 sold of $20,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 16, 2015 · D · $1,500,000 sold of $10,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 30, 2011 · D · $1,083,950 sold of $1,083,950 · 14 investors · min. $1 · role: Executive Officer, Director EDGAR ↗
  • Feb 3, 2010 · D · $1,700,000 sold of $2,400,000 · 18 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $114.8M from 26 investors (96% of the $120M target) as of the latest filing. David is listed as director, executive officer on 10 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AH
Other Health Care

Adigica Health, Inc.

San Diego, CA · Aug 17, 2016 → Mar 1, 2021 · 5 filings
  • Mar 1, 2021 · D · $1,025,483 sold of $3,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 27, 2020 · D · $450,000 sold of $650,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 7, 2019 · D · $11,197,377 sold of $13,197,377 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 7, 2019 · D · $7,510,197 sold of $7,510,197 · 40 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 17, 2016 · D · $1,606,667 sold of $5,008,255 · 10 investors · min. No minimum reported · role: Director (Executive Chairman) EDGAR ↗

Raised $11.2M from 40 investors (100% of the $3M target) as of the latest filing. David is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OT
Biotechnology · group: Oncternal Therapeutics

Oncternal Therapeutics, Inc.

San Diego, CA · Jun 3, 2020 → Dec 22, 2020 · 5 filings
  • Dec 22, 2020 · D · $6,467,063 sold of $6,467,063 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 24, 2020 · D · $1,687,501 sold of $1,687,501 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 9, 2020 · D · $382,549 sold of $382,549 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 3, 2020 · D · $3,456,308 sold of $3,456,308 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 3, 2020 · D · $2,814,260 sold of $2,814,260 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $48.5M from 12 investors (100% of the $6.47M target) as of the latest filing. David is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

DT
Biotechnology · group: Dermata Therapeutics

Dermata Therapeutics, LLC

San Diego, CA · Feb 3, 2015 → Dec 10, 2020 · 5 filings
  • Dec 10, 2020 · D · $3,000,000 sold of Indefinite · 37 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Managing Member of Managing Member of Issuer) EDGAR ↗
  • May 7, 2018 · D · $5,000,000 sold of Indefinite · 49 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Managing Member of Managing Member of Issuer) EDGAR ↗
  • May 7, 2018 · D · $6,906,244 sold of Indefinite · 49 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Managing Member of Managing Member of Issuer) EDGAR ↗
  • Jun 12, 2015 · D · $651,305 sold of Indefinite · 7 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Managing Member of Managing Member of the Issuer) EDGAR ↗
  • Feb 3, 2015 · D · $608,050 sold of $608,050 · 7 investors · min. No minimum reported · role: Executive Officer, Director, Promoter (Managing Member of Managing Member of the Issuer) EDGAR ↗

Raised $6.91M from 49 investors as of the latest filing. David is listed as executive officer, director, promoter on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

NP
Biotechnology

Neurana Pharmaceuticals, Inc.

San Diego, CA · Mar 10, 2017 → Feb 26, 2020 · 4 filings
  • Feb 26, 2020 · D/A · $41,888,250 sold of $64,888,250 · 14 investors · min. No minimum reported · role: Director (Chairman of the Board of Directors) EDGAR ↗
  • May 14, 2018 · D · $29,888,249 sold of $64,888,250 · 14 investors · min. No minimum reported · role: Director, Executive Officer (Chairman of the Board of Directors, Acting President and CEO) EDGAR ↗
  • May 14, 2018 · D/A · $3,818,750 sold of $3,818,750 · 8 investors · min. No minimum reported · role: Director, Executive Officer (Chairman of the Board of Directors, Acting President and CEO) EDGAR ↗
  • Mar 10, 2017 · D · $1,050,000 sold of $3,500,000 · 3 investors · min. No minimum reported · role: Director (Chairman of the Board of Directors) EDGAR ↗

Raised $41.9M from 14 investors (65% of the $64.9M target) as of the latest filing. David is listed as director, executive officer on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ZH
Other Health Care

Zerigo Health, Inc.

San Diego, CA · Jul 31, 2014 → Nov 15, 2019 · 11 filings
  • Nov 15, 2019 · D/A · $2,606,762 sold of $3,000,300 · 12 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Nov 6, 2019 · D · $15,787,828 sold of $21,787,829 · 19 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Mar 7, 2019 · D · $1,771,636 sold of $3,000,300 · 9 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Jul 3, 2018 · D · $1,017,000 sold of $1,500,000 · 7 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Jul 27, 2017 · D/A · $6,481,690 sold of $7,000,000 · 51 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Jul 24, 2017 · D · $3,216,106 sold of $5,001,000 · 38 investors · min. No minimum reported · role: Director (Chairman of the Board) EDGAR ↗
  • Jun 24, 2016 · D/A · $1,958,690 sold of $4,500,000 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 18, 2016 · D · $37,000 sold of $37,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 18, 2016 · D · $25,000 sold of $25,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 3, 2015 · D/A · $1,394,690 sold of $2,010,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 31, 2014 · D · $150,440 sold of $2,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $43M from 51 investors (100% of the $3M target) as of the latest filing. David is listed as director on 11 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

B
Biotechnology

BIOCEPT INC

San Diego, CA · Dec 23, 2015 → Jun 6, 2019 · 6 filings
  • Jun 6, 2019 · D · $0 sold of $10,134,300 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 29, 2019 · D · $0 sold of $7,437,500 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 3, 2018 · D · $0 sold of $2,409,304 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 14, 2017 · D · $2,200,000 sold of $4,351,958 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 10, 2017 · D · $0 sold of $5,400,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 23, 2015 · D · $1,000,000 sold of $15,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.6M from 13 investors (36% of the $10.1M target) as of the latest filing. David is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RM
Biotechnology

Recros Medica, Inc.

San Diego, CA · Sep 10, 2014 → Feb 14, 2019 · 5 filings
  • Feb 14, 2019 · D · $4,121,779 sold of $10,000,000 · 47 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 25, 2017 · D/A · $4,413,250 sold of $9,000,000 · 44 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 23, 2016 · D/A · $1,365,600 sold of $1,920,000 · 5 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jul 6, 2016 · D · $950,000 sold of $3,070,400 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 10, 2014 · D · $250,000 sold of $5,000,000 · 2 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $4.41M from 47 investors (44% of the $10M target) as of the latest filing. David is listed as director, executive officer on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OT
Biotechnology · group: Oncternal Therapeutics

Oncternal Therapeutics, Inc.

San Diego, CA · Mar 5, 2014 → Nov 21, 2018 · 10 filings
  • Nov 21, 2018 · D · $17,000,000 sold of $24,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 27, 2017 · D · $6,850,397 sold of $11,251,125 · 121 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 23, 2017 · D/A · $17,874,045 sold of $23,504,838 · 111 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 9, 2016 · D/A · $11,281,734 sold of $20,000,000 · 95 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 20, 2016 · D/A · $6,083,738 sold of $20,000,000 · 72 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 8, 2016 · D · $150,000 sold of $3,300,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 8, 2016 · D · $13,135,714 sold of $13,135,714 · 26 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 10, 2016 · D/A · $3,709,993 sold of $10,000,000 · 39 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 7, 2015 · D · $3,149,995 sold of $10,000,000 · 30 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 5, 2014 · D · $3,090,000 sold of $3,280,000 · 26 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $17.9M from 121 investors (74% of the $24M target) as of the latest filing. David is listed as director on 10 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

C
Other Health Care · group: Colorescience

Colorescience Inc

Carlsbad, CA · May 31, 2013 → Mar 27, 2017 · 3 filings
  • Mar 27, 2017 · D · $4,196,471 sold of $4,196,471 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 22, 2014 · D · $15,000,000 sold of $15,000,000 · 32 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 31, 2013 · D · $10,000,000 sold of $10,000,000 · 53 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $15M from 53 investors (100% of the $4.2M target) as of the latest filing. David is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

M
Biotechnology

MDREJUVENA, INC.

San Diego, CA · Nov 3, 2014 → Dec 19, 2016 · 3 filings
  • Dec 19, 2016 · D · $2,420,164 sold of $5,000,000 · 7 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Oct 22, 2015 · D/A · $3,799,723 sold of $5,100,000 · 19 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Nov 3, 2014 · D · $250,000 sold of $5,100,000 · 1 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $3.8M from 19 investors (76% of the $5M target) as of the latest filing. David is listed as executive officer, director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

IP
Pharmaceuticals

IDUN PHARMACEUTICALS INC

San Diego, CA · Feb 25, 2014 → Jul 13, 2015 · 4 filings
  • Jul 13, 2015 · D · $1,125,000 sold of $1,500,000 · 30 investors · min. $1 · role: Executive Officer, Director EDGAR ↗
  • Feb 4, 2015 · D/A · $2,000,044 sold of $2,000,044 · 30 investors · min. $1 · role: Executive Officer, Director EDGAR ↗
  • Oct 9, 2014 · D/A · $500,011 sold of $500,011 · 30 investors · min. $1 · role: Executive Officer, Director EDGAR ↗
  • Feb 25, 2014 · D · $275,006 sold of $275,006 · 30 investors · min. $1 · role: Executive Officer, Director EDGAR ↗

Raised $2M from 30 investors (100% of the $1.5M target) as of the latest filing. David is listed as executive officer, director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

H
Biotechnology · group: Histogen

Histogen Inc.

San Diego, CA · Oct 28, 2010 → Jun 13, 2013 · 3 filings
  • Jun 13, 2013 · D · $1,001,551 sold of $1,001,551 · 21 investors · min. $1 · role: Director EDGAR ↗
  • Feb 17, 2011 · D · $25,275,507 sold of $25,275,507 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 28, 2010 · D · $5,000,000 sold of $5,000,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.3M from 21 investors (100% of the $1M target) as of the latest filing. David is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

RD
Biotechnology

Ridge Diagnostics, Inc.

La Jolla, CA · Jun 11, 2010 → Apr 18, 2013 · 3 filings
  • Apr 18, 2013 · D · $250,000 sold of $2,500,000 · 8 investors · min. $1 · role: Director EDGAR ↗
  • Mar 19, 2012 · D · $6,605,440 sold of $6,605,440 · 32 investors · min. $1 · role: Director EDGAR ↗
  • Jun 11, 2010 · D · $577,000 sold of $3,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.61M from 32 investors (100% of the $2.5M target) as of the latest filing. David is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

C
Other · group: Colorescience

Colorescience

Carsbad, CA · Dec 31, 2012
  • Dec 31, 2012 · D · $15,255,065 sold of $15,255,065 · 84 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $15.3M from 84 investors (100% of the $15.3M target) as of the latest filing. David is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AC
Other Health Care

Agility Clinical, Inc.

Carlsbad, CA · Aug 14, 2012
  • Aug 14, 2012 · D · $390,000 sold of $1,000,000 · 6 investors · min. $1 · role: Executive Officer, Director EDGAR ↗

Raised $390K from 6 investors (39% of the $1M target) as of the latest filing. David is listed as executive officer, director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

S
Pharmaceuticals

SKINMEDICA INC

Carlsbad, CA · Jun 12, 2009 → Jan 13, 2012 · 2 filings
  • Jan 13, 2012 · D · $16,759,991 sold of $17,125,000 · 2 investors · min. $1 · role: Director EDGAR ↗
  • Jun 12, 2009 · D · $9,438,712 sold of $9,438,712 · 15 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $16.8M from 15 investors (98% of the $17.1M target) as of the latest filing. David is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

SP
Pharmaceuticals

Somaxon Pharmaceuticals, Inc.

Solana Beach, CA · Jul 15, 2009
  • Jul 15, 2009 · D · $5,999,990 sold of $5,999,990 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6M from 16 investors (100% of the $6M target) as of the latest filing. David is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (5)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • David Hale — NY, 2 issuers, Jun 25, 2009 → Sep 5, 2025 · no shared issuer
  • David Hale — TX, 1 issuer, Jun 30, 2014 → Jun 30, 2014 · no shared issuer
  • David E. Hale — MA, 1 issuer, Aug 7, 2014 → Aug 7, 2014 · no shared issuer
  • David P. Hale — AL, 1 issuer, Sep 12, 2018 → Oct 5, 2021 · no shared issuer
  • David Hale — IL, 1 issuer, Aug 9, 2022 → Aug 9, 2022 · no shared issuer

People around David 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

HB
Management entity

Hale BioPharma Ventures, LLC

Promoter, Executive Officer · 5 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

KS
Person

Kathleen D. Scott

Executive Officer, Director · 23 shared filings (6 issuers) · also on 1 other issuer

Kathleen D. Scott is on 7 issuers in total — a repeat sponsor. Their page lists every one.

CG
Person

Cam L. Garner

Director · 18 shared filings (3 issuers) · also on 9 other issuers

Cam L. Garner is on 12 issuers in total — a repeat sponsor. Their page lists every one.

JD
Person

James B. Breitmeyer, M.D., Ph.D.

Executive Officer, Director · 13 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

GP
Person

Gerald T. Proehl

Director, Promoter, Executive Officer · 12 shared filings (3 issuers) · also on 3 other issuers

Gerald T. Proehl is on 6 issuers in total — a repeat sponsor. Their page lists every one.

MF
Person

Mary Fisher

Executive Officer, Director · 11 shared filings (4 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

RB
Person

Rex Bright

Director · 10 shared filings (3 issuers) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

CC
Person

Craig C. Chambliss

Executive Officer, Director · 10 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

SG
Person

Scott L. Glenn

Executive Officer, Director · 10 shared filings (1 issuer) · also on 12 other issuers

Scott L. Glenn is on 13 issuers in total — a repeat sponsor. Their page lists every one.

LO
Person

Lauren G. Otsuki

Executive Officer · 9 shared filings (1 issuer) · also on 5 other issuers

Lauren G. Otsuki is on 6 issuers in total — a repeat sponsor. Their page lists every one.

KL
Person

Kevin Li

Director · 8 shared filings (1 issuer) · also on 4 other issuers

Kevin Li is on 5 issuers in total — a repeat sponsor. Their page lists every one.

PK
Person

Paul Klingenstein

Director · 7 shared filings (2 issuers) · also on 5 other issuers

Paul Klingenstein is on 7 issuers in total — a repeat sponsor. Their page lists every one.

SM
Person

Steven Mento

Executive Officer, Director · 7 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

WL
Person

William R. LaRue

Director · 7 shared filings (3 issuers) · also on 2 other issuers

William R. LaRue is on 5 issuers in total — a repeat sponsor. Their page lists every one.

RV
Person

Richard G. Vincent

Executive Officer · 7 shared filings (2 issuers) · also on 4 other issuers

Richard G. Vincent is on 6 issuers in total — a repeat sponsor. Their page lists every one.

PB
Person

Priyanka Belawat

Director · 7 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

JB
Person

John T. Buhler

Director · 7 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

DJ
Person

David Johnson

Director · 6 shared filings (1 issuer) · also on 16 other issuers

David Johnson is on 17 issuers in total — a repeat sponsor. Their page lists every one.

BD
Person

Brian H. Dovey

Director · 6 shared filings (3 issuers) · also on 12 other issuers

Brian H. Dovey is on 15 issuers in total — a repeat sponsor. Their page lists every one.

IR
Person

Ivor Royston

Director · 6 shared filings (1 issuer) · also on 5 other issuers

Ivor Royston is on 6 issuers in total — a repeat sponsor. Their page lists every one.

CC
Person

Charles J. Cashion

Director, Executive Officer · 6 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

BH
Person

Bruce Huebner

Director · 6 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

BG
Person

Bruce E. Gerhardt

Director · 6 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

SM
Person

Shahzad Malik

Director · 6 shared filings (2 issuers) · also on 6 other issuers

Shahzad Malik is on 8 issuers in total — a repeat sponsor. Their page lists every one.

LL
Person

Louis Lacasse

Director · 6 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

WW
Person

Wendell Wierenga

Director · 6 shared filings (2 issuers) · also on 3 other issuers

Wendell Wierenga is on 5 issuers in total — a repeat sponsor. Their page lists every one.

MW
Person

M. Faye Wilson

Director · 6 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as David F. Hale. Their page shows their other deals.

MN
Person

Michael Nall

Executive Officer, Director · 6 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

LA
Person

Lyle Arnold

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

MC
Person

Marsha A. Chandler

Director · 6 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

GS
Person

George Stuart

Executive Officer · 6 shared filings (1 issuer)

Listed on the same filings as David F. Hale. Their page shows their other deals.

TE
Person

Theodore Ebel

Executive Officer · 5 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

WD
Person

William Gerber, M.D.

Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

BD
Person

Brian Dorsey

Executive Officer, Director · 5 shared filings (2 issuers) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

JS
Person

James Scopa

Director · 5 shared filings (2 issuers) · also on 5 other issuers

James Scopa is on 7 issuers in total — a repeat sponsor. Their page lists every one.

CT
Person

Charles P. Theuer

Director · 5 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as David F. Hale. Their page shows their other deals.

CM
Person

Cathy McCarthy

Director, Executive Officer · 5 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as David F. Hale. Their page shows their other deals.

CG
Person

Cam Gallagher

Director · 5 shared filings (1 issuer) · also on 9 other issuers

Cam Gallagher is on 10 issuers in total — a repeat sponsor. Their page lists every one.

SD
Person

Steven J. Mento, Ph.D.

Executive Officer, Director · 5 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

MP
Person

Marc O. Perret

Director · 5 shared filings (2 issuers)

Listed on the same filings as David F. Hale. Their page shows their other deals.

The team behind the deals

C
Sponsor group

Colorescience

2 issuers · 7 filings · $18.3M reported sold · 2012–2020

One team, 2 deal companies. David F. Hale is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David F. Hale.

DT
Sponsor group

Dermata Therapeutics

2 issuers · 10 filings · $7.12M reported sold · 2015–2026

One team, 2 deal companies. David F. Hale is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David F. Hale.

OT
Sponsor group

Oncternal Therapeutics

2 issuers · 19 filings · $23.5M reported sold · 2014–2020

One team, 2 deal companies. David F. Hale is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David F. Hale.

H
Sponsor group

Histogen

2 issuers · 15 filings · $20.3M reported sold · 2010–2022

One team, 2 deal companies. David F. Hale is listed on 1 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name David F. Hale.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.

Other offering types (Regulation A and Regulation Crowdfunding)

None found in sources searched.

Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Carsbad, CA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗California — find the county court ↗Los Angeles Superior Court case search ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

California Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when David F. Hale appears on a new Form D, or when a court case or SEC action is matched to them. See plans →